

Metal-Free CH–CH-Type Cross-Coupling of Arenes and Alkynes Directed by a Multifunctional Sulfoxide Group

José A. Fernández-Salas, Andrew J. Eberhart, and David J. Procter*

School of Chemistry, University of Manchester, Oxford Road, Manchester, M13 9PL, U.K.

Supporting Information


ABSTRACT: A metal-free CH–CH-type coupling of arenes and alkynes, mediated by a multifunctional sulfoxide directing group, exploits nonprefunctionalized coupling partners, proceeds under mild conditions, is operationally simple, and exhibits high functional group tolerance. The products of the CH–CH coupling are highly versatile, and the metal-free process can be used for the construction and late-stage modification of important molecular scaffolds.

Carbon–carbon bond formation is a challenging objective that is essential in almost any synthetic endeavor that involves the construction or manipulation of molecular architecture.^{1,2} In particular, metal-catalyzed C–H functionalization has become an established and more atom-economical way to construct C–C bonds with a wide selection of directing groups available to control processes involving C–H bonds on aromatic rings (Scheme 1A).³ Furthermore, CH–CH-type cross-coupling, so-called cross-dehydrogenative coupling (CDC), has been developed that obviates the need for prefunctionalization of either coupling partner,⁴ although issues

of chemo- and regioselectivity and a dependence on harsh conditions and stoichiometric oxidants remain issues that limit the broad take-up of such technology (Scheme 1A).⁴ The majority of C–H cross-coupling processes are mediated by platinum group metals, and this leads to potential issues of supply risk⁵ and metal contamination of products.^{2a–c,6,7} Thus, despite remarkable recent advances in C–H cross-coupling, the development of complementary, metal-free CH–CH-type cross-coupling processes that use readily available non-prefunctionalized starting materials and that operate under mild conditions is an outstanding challenge.

Here we report a metal-free CH–CH-type strategy that allows the selective coupling of aromatic centers to propargylic centers in alkynes at the expense of two C–H bonds: CAr(sp²)–H and C(sp³)–H bonds. A sulfoxide directing group in the arene plays a multifunctional role in the metal-free cross-coupling, capturing, activating, and delivering⁸ the pronucleophilic alkyne partner, controlling the regiochemical outcome of the coupling, and ensuring that no over-reaction takes place to give byproducts (Scheme 1B).^{9,10} Key to successful coupling is the proposed formation and rearrangement of alkenyl sulfonium salt intermediates I.^{11,12} The products of cross-coupling are challenging targets for current metal-mediated methods.

Scheme 1. (A) Metal-Catalyzed C–H and CH–CH Cross-Coupling; (B) Metal-Free, CH–CH-Type Cross-Coupling of Arenes and Alkynes Mediated by a Sulfoxide Directing Group (DG)^a




^aX–Y = electrophilic activator of sulfoxide.

Our study began by investigating the cross-coupling reaction between arene sulfoxide **1a** and butyne **2a** (see Supporting Information for optimization studies). Aiming to develop an operationally simple protocol, we explored the use of commercially available Tf₂O (1,1,1-trifluoromethanesulfonic anhydride) and 2,6-lutidine to mediate the proposed metal-free cross-coupling.^{8a} Unfortunately, in both MeCN and CH₂Cl₂, only traces of the desired product **3a** were observed. The role of the base and the temperature at which the activating agent was added were then investigated. Interestingly, if Tf₂O was added at –78 °C in the presence of K₂CO₃, the desired process was observed and a 65% isolated yield of the product of CH–CH-type coupling **3a** was obtained. When 2,6-lutidine was used as base and added at 0 °C after 45 min, the cross-coupling proceeded, delivering **3a** in good isolated yield (ca. 75%) after 16 h at 65 °C (or 3 h with microwave heating).

Having optimized the reaction conditions, we next investigated the scope of the metal-free CH–CH-type cross-coupling with regard to the alkyne partner. A range of readily available, simple and functionalized alkyne partners **2a–k** were employed in the study (Table 1). Arene sulfoxide **1a** underwent

Received: December 2, 2015

Published: January 8, 2016

Table 1. Alkyne Substrate Scope in the Metal-Free CH–CH-Type Cross-Coupling of Alkynes with Arenes Bearing a Sulfoxide Directing Group^a


^aTf₂O (1.3 equiv) was added to a mixture of **1** (0.15 mmol) and **2** (1.3 equiv) in CH₂Cl₂ (0.2 M) at –78 °C. After 15 min at the same temperature, the mixture was stirred at 0 °C for 30 min. 2,6-Lutidine (3 equiv) was then added. The reaction mixture was heated at 65 °C for 16 h.

efficient coupling with sterically demanding 4,4-dimethylpent-2-yne **2b** and benzyl-substituted alkyne **2c** to give good isolated yields of the desired products **3b** and **3c**, respectively. Similarly, silyl-substituted alkynes **2f** and **2g** underwent efficient cross-coupling to give versatile alkyne products **3f** and **3g**. Attractively, protected alkyne coupling products allow access to a range of products via deprotection and derivatization. Important bromide and CF₃ substituents in the alkyne were also compatible with the metal-free coupling (preparation of **3j** and **3k**). Pleasingly, challenging metal-free couplings involving secondary sp³-propargylic C–H bonds were possible and resulted in new C–C bonds despite significant steric congestion: alkynes **2d**, **2e**, **2h**, and **2i** underwent coupling to give branched coupling products **3d**, **3e'**, **3h**, **3i**, **3o**, and **3p** in moderate to high yield. Finally, an arene bearing a methyl sulfinyl directing group could also be used in the cross-coupling: treatment of **1b** with alkynes **2b**, **2f**, **2g**, **2h**, and **2i** gave the desired coupling products **3l–p**, respectively (Table 1).

Cross-coupling proceeded efficiently between a range of readily available starting arenes bearing a variety of substituents and alkynes **2a**, **2f**, and **2g**. Arenes bearing electron-donating methoxy groups showed lower reactivity, leading to coupled products **3q** and **3r** in moderate yield. Less electron releasing

methyl substituents on the arene were tolerated, and **3y** was obtained in 60% yield. Electron-withdrawing groups on the arene partner were well tolerated in the metal-free CH–CH type cross-coupling. For example, arene substrates bearing CF₃ groups in *ortho*, *meta*, and *para* positions led to coupled products in excellent yield (**3s–3u**). Arenes containing bromide and chloride substituents also underwent coupling with high efficiency (**3v**, **3w**, and **3x**). It is important to note that the presence of halides is often incompatible with metal-mediated cross-coupling procedures.

Nitro and sulfone substituents were also tolerated, and arenes bearing these groups underwent successful coupling to give **3z** and **3aa**. The metal-free CH–CH-type cross-coupling also proceeded in the presence of unprotected ketones and aldehydes: adducts **3ab**, **3ac**, **3af**, and **3ag** were obtained in 61–82% yield. Substitution in the aryl unit of the sulfoxide-directing group was also tolerated with coupling taking place selectively on the more electron-rich ring (formation of **3ad**). Finally, heterocyclic coupling partners also underwent coupling with alkynes to give **3ae**, **3af**, **3ag**, and **3ah** in moderate to good yield thus illustrating the potential of the process for the manipulation of heteroarene platforms (Table 2).


Table 2. Study of Arene Substrate Scope in the Metal-Free CH–CH-Type Cross-Coupling of Arenes with Alkynes^a

^aSee Table 1 for conditions. Isolated yields. ^bRatio in brackets refers to regioselectivity. Alkylation away from the *meta* substituent gives the major product.

A possible mechanism for coupling with but-2-yne **2a** is shown in Scheme 2. The alkyne partner is captured and activated by the triflated sulfoxide **II** at low temperature^{8–10} giving rise to vinyl triflate **IV** (cf. **I** in Scheme 1B). In the presence of base, **IV** may be deprotonated to give sulfonium ylide **V** and [3,3]-sigmatropic rearrangement of **V**¹³ at elevated temperature followed by rearomatization delivers CH–CH-type cross-coupling product **3**. In support of the above, quenching reactions between sulfoxide-bearing arenes **1a** and **1b** and alkyne **2a** at 0 °C prior to the addition of base resulted in complete conversion to alkenylsulfonium salts (see Supporting Information).^{11,12}

The selective onward reaction of alkenylsulfonium intermediate **IV** (R¹ = Me) is key to the success of the cross-coupling. Alkynes bearing large substituents are particularly

Scheme 2. Proposed Mechanism for the Metal-Free CH–CH-Type Cross-Coupling of But-2-yne **2a** with Arenes Bearing a Sulfoxide Directing Group



effective, as they control the regiochemistry of the addition to the activated sulfoxide **II** and give rise to alkenylsulfonium intermediates **IV** bearing large R^2 groups.¹⁴ These large R^2 groups block undesired deprotonation and nucleophilic demethylation of the SMe group, and hydrolysis of the triflate in **IV**.¹¹


The products of cross-coupling are versatile building blocks for organic synthesis and are difficult to access selectively using current methods. By focusing on metal-free transformations,¹⁵ deprotection of adduct **3n** delivered **4** or isomerization product **5**, depending on the conditions employed. Notably, arylalkyne **5** is the product of a formal metal-free, C–H Sonogashira-type reaction (Scheme 3A).¹⁶

Pleasingly, a sulfur atom in a validated drug scaffold can be used to direct the metal-free CH–CH cross-coupling. Sulfide scaffold **6** is an intermediate in the synthesis of the topical retinoid Tazarotene (Tazorac) **10**.¹⁷ Activation of **6** by sulfur oxidation and CH–CH cross-coupling with alkyne partner **2g** gave **8** in good yield. High yielding deprotection/isomerization then gave alkylation product **9**. Attractively, the metal-free sulfoxide directed CH–CH coupling is orthogonal to the Pd-catalyzed alkylation of the C–Br bond used in the preparation of the drug (Scheme 3B).^{17,18} Functionalized benzothiophene **11** is a key intermediate in the synthesis of the antipsychotic drug **12**: an agonist of the G-protein coupled receptor 52.¹⁹ The crucial C–C bond in **11** is typically prepared by stoichiometric metalation of the arene.²⁰ The sulfoxide-directed CH–CH process allows medically relevant benzothiophene **11** to be prepared from **1i** in four metal-free steps: CH–CH cross-coupling, TBAF deprotection, I_2 -mediated heterocyclization,²¹ and $NaBH_4$ reduction of the intermediate benzothiophene aldehyde delivers **11** in 57% overall yield (Scheme 3C).


In summary, we have developed an operationally simple, metal-free CH–CH-type cross-coupling of arenes and alkynes that proceeds under mild conditions. The process is mediated by a sulfoxide-directing group that captures and activates the alkyne coupling partner before delivery to the arene and C–C bond formation. The products of cross-coupling are difficult to access using current metal-mediated procedures and are rich in

Scheme 3. Sulfoxide-Directed Metal-Free CH–CH-Type Cross-Coupling for Scaffold Construction and Late-Stage Modification


A. Metal-free CH–CH propargylation delivers products of formal alkylation



B. Metal-free CH–CH cross-coupling in a validated drug scaffold



C. CH–CH cross-coupling in a metal-free route to a medicinal chem. building block



synthetic potential. For example, they are readily converted to products of formal metal-free arene C–H alkylation and to important benzothiophene motifs, as exemplified by the metal-free synthesis of a precursor to an antipsychotic drug. Furthermore, sulfur in a validated heterocyclic drug scaffold can be used to direct metal-free CH–CH cross-coupling thus facilitating late-stage scaffold elaboration.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.5b12579.

Optimization table, mechanistic studies, experimental details, characterization data and spectra (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: david.j.procter@manchester.ac.uk

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

EPSRC (Established Career Fellowship to D.J.P.; Postdoctoral Fellowship to J.A.F.-S.; Doctoral Prize to A.J.E.) and The Leverhulme Trust (Fellowship to D.J.P.).

REFERENCES

- (1) Corey, E. J.; Cheng, X. M. *The Logic of Chemical Synthesis*; John Wiley & Sons: New York, 1989.
- (2) (a) Magano, J.; Dunetz, J. R. *Chem. Rev.* **2011**, *111*, 2177. (b) Magano, J.; Dunetz, J. R. *Transition-Metal-Catalyzed Couplings in Process Chemistry: Case Studies From the Pharmaceutical Industry*; Wiley: 2013. (c) Roughley, S. D.; Jordan, A. M. *J. Med. Chem.* **2011**, *54*, 3451. (d) Crabtree, R. H. *The Organometallic Chemistry of Transition Metals*; Wiley Interscience: New York, 2005. (e) Tsuji, J. *Transition Metal Reagents and Catalysts: Innovations in Organic Synthesis*; Wiley: Chichester, 2002. (f) de Vries, J. In *Organometallics as Catalysts in the Fine Chemical Industry*; Beller, M., Blaser, H. -U., Eds.; Springer: Berlin Heidelberg, 2012; Vol. 42, p 1. (g) Johansson Seechurn, C. C. C.; Kitching, M. O.; Colacot, T. J.; Snieckus, V. *Angew. Chem., Int. Ed.* **2012**, *51*, 5062. (h) Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. *Angew. Chem., Int. Ed.* **2005**, *44*, 4442. (i) Corbet, J.-P.; Mignani, G. *Chem. Rev.* **2006**, *106*, 2651.
- (3) (a) Chen, Z.; Wang, B.; Zhang, J.; Yu, W.; Liu, Z.; Zhang, Y. *Org. Chem. Front.* **2015**, *2*, 1107. (b) Wencel-Delord, J.; Glorius, F. *Nat. Chem.* **2013**, *5*, 369. (c) McMurray, L.; O'Hara, F.; Gaunt, M. J. *Chem. Soc. Rev.* **2011**, *40*, 1885. (d) Gutekunst, W. R.; Baran, P. S. *Chem. Soc. Rev.* **2011**, *40*, 1976. (e) Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. *Angew. Chem., Int. Ed.* **2009**, *48*, 5094. (f) Godula, K.; Sames, D. *Science* **2006**, *312*, 67. (g) Labinger, J. A.; Bercaw, J. E. *Nature* **2002**, *417*, 507. (h) Colby, D. A.; Tsai, A. S.; Bergman, R. G.; Ellman, J. A. *Acc. Chem. Res.* **2012**, *45*, 814. (i) Engle, K. M.; Mei, T.-S.; Wasa, M.; Yu, J.-Q. *Acc. Chem. Res.* **2012**, *45*, 788. (j) Neufeldt, S. R.; Sanford, M. S. *Acc. Chem. Res.* **2012**, *45*, 936. (k) Alberico, D.; Scott, M. E.; Lautens, M. *Chem. Rev.* **2007**, *107*, 174. (l) Arockiam, P. B.; Bruneau, C.; Dixneuf, P. H. *Chem. Rev.* **2012**, *112*, 5879. (m) Daugulis, O.; Do, H.-Q.; Shabashov, D. *Acc. Chem. Res.* **2009**, *42*, 1074. (n) Daugulis, O.; Roane, J.; Tran, L. D. *Acc. Chem. Res.* **2015**, *48*, 1053.
- (4) (a) Kuhl, N.; Hopkinson, M. N.; Wencel-Delord, J.; Glorius, F. *Angew. Chem., Int. Ed.* **2012**, *51*, 10236. (b) Li, C.-J. *Acc. Chem. Res.* **2009**, *42*, 335. (c) Yeung, C. S.; Dong, V. M. *Chem. Rev.* **2011**, *111*, 1215. (d) Kozhushkov, S. I.; Ackermann, L. *Chem. Sci.* **2013**, *4*, 886. (e) Narayan, R.; Matcha, K.; Antonchick, A. P. *Chem. - Eur. J.* **2015**, *21*, 14678.
- (5) (a) The Risk list. British Geological Survey (2012); https://www.bgs.ac.uk/news/NEWS/Risk_List_2012_Press_Release.pdf. (b) Sun, C.-L.; Shi, Z.-J. *Chem. Rev.* **2014**, *114*, 9219.
- (6) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Guideline for Elemental Impurities Q3D (2014); <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm371025.pdf>.
- (7) Usluer, Ö.; Abbas, M.; Wantz, G.; Vignau, L.; Hirsch, L.; Grana, E.; Brochon, C.; Cloutet, E.; Hadziioannou, G. *ACS Macro Lett.* **2014**, *3*, 1134.
- (8) For reviews of Pummerer processes and selected recent applications, see: (a) Smith, L. H. S.; Coote, S. C.; Sneddon, H. F.; Procter, D. J. *Angew. Chem., Int. Ed.* **2010**, *49*, 5832. (b) Akai, S.; Kita, Y. *Top. Curr. Chem.* **2007**, *274*, 35. (c) Bur, S. K.; Padwa, A. *Chem. Rev.* **2004**, *104*, 2401. (d) Murakami, K.; Yorimitsu, H.; Osuka, A. *Angew. Chem., Int. Ed.* **2014**, *53*, 7510. (e) Huang, X.; Patil, M.; Farès, C.; Thiel, W.; Maulide, N. *J. Am. Chem. Soc.* **2013**, *135*, 7312. (f) Huang, X.; Maulide, N. *J. Am. Chem. Soc.* **2011**, *133*, 8510. (g) Ookubo, Y.; Wakamiya, A.; Yorimitsu, H.; Osuka, A. *Chem. - Eur. J.* **2012**, *18*, 12690. (h) Kobatake, T.; Fujino, D.; Yoshida, S.; Yorimitsu, H.; Oshima, K. *J. Am. Chem. Soc.* **2010**, *132*, 11838. (i) Kobatake, T.; Yoshida, S.; Yorimitsu, H.; Oshima, K. *Angew. Chem., Int. Ed.* **2010**, *49*, 2340.
- (9) For sulfoxide-directed couplings using allylsilanes: (a) Eberhart, A. J.; Cicoira, C.; Procter, D. J. *Org. Lett.* **2013**, *15*, 3994. (b) Eberhart, A. J.; Imbriglio, J. E.; Procter, D. J. *Org. Lett.* **2011**, *13*, 5882.
- (10) For sulfoxide-directed couplings using propargylsilanes: (a) Eberhart, A. J.; Procter, D. J. *Angew. Chem., Int. Ed.* **2013**, *52*, 4008. (b) Eberhart, A. J.; Shrivs, H. J.; Álvarez, E.; Carrèr, A.; Zhang, Y.; Procter, D. J. *Chem. - Eur. J.* **2015**, *21*, 7428. (c) Eberhart, A. J.; Shrivs, H.; Zhang, Y.; Carrèr, A.; Parry, A. V. S.; Tate, D. J.; Turner, M. L.; Procter, D. J. *Chem. Sci.* **2016**, DOI: 10.1039/C5SC03823E.
- (11) Nenajdenko, V. G.; Verteletzkiy, P. V.; Balenkova, E. S. *Synthesis* **1997**, 1997, 351.
- (12) Nenajdenko, V. G.; Balenkova, E. S. *Russ. J. Org. Chem.* **2003**, *39*, 291.
- (13) (a) Huang, X.; Klimczyk, S.; Maulide, N. *Synthesis* **2012**, *44*, 175. (b) Nyong, A. M.; Rainier, J. D. *J. Org. Chem.* **2005**, *70*, 746. (c) Novikov, A. V.; Kennedy, A. R.; Rainier, J. D. *J. Org. Chem.* **2003**, *68*, 993.
- (14) The observed regioselectivity in the formation of **III** may arise from hyperconjugative stabilization of the β -vinyl cation by the alkyl and trialkylsilyl groups. Wierschke, S. G.; Chandrasekhar, J.; Jorgensen, W. L. *J. Am. Chem. Soc.* **1985**, *107*, 1496.
- (15) For low-cost metal-catalyzed cross-coupling of organosulfur substrates, see: (a) Baralle, A.; Otsuka, S.; Guérin, V.; Murakami, K.; Yorimitsu, H.; Osuka, A. *Synlett* **2015**, *26*, 327. (b) Pan, F.; Shi, Z.-J. *ACS Catal.* **2014**, *4*, 280. (c) Dubbaka, S. R.; Vogel, P. *Angew. Chem., Int. Ed.* **2005**, *44*, 7674. See also ref 9b.
- (16) Chinchilla, R.; Najera, C. *Chem. Soc. Rev.* **2011**, *40*, 5084.
- (17) (a) Chandraratna, R. A. S. U.S. Patent 5,602,130, 1997. (b) Kumar, B. V. S.; Patil, V. D.; Raut, C. N.; Bhirud, S. B.; Chandrasekhar, B. WO 2005/003125 A1, 2005.
- (18) Frigoli, S.; Fuganti, C.; Malpezzi, L.; Serra, S. *Org. Process Res. Dev.* **2005**, *9*, 646.
- (19) Setoh, M.; Ishii, N.; Kono, M.; Miyanoana, Y.; Shiraishi, E.; Harasawa, T.; Ota, H.; Odani, T.; Kanzaki, N.; Aoyama, K.; Hamada, T.; Kori, M. *J. Med. Chem.* **2014**, *57*, 5226.
- (20) Agejas-Chicharro, J.; Bueno Melendo, A. B.; Camp, N. P.; Gilmore, J.; Jimenez-Aguado, A. M.; Lamas-Peteira, C.; Marcos-Llorente, A.; Mazanetz, M. P.; Montero Salgado, C.; Timms, G. H.; Williams, A. C. Pharmaceutical compounds. US 2004/122001 A1, 2004.
- (21) Parvatkar, P. T.; Parameswaran, P. S.; Tilve, S. G. *Chem. - Eur. J.* **2012**, *18*, 5460.